Private placement funds secured by Revive Therapeutics concluded in a second round.
Revive Therapeutics Closes Second Tranche of Private Placement
Revive Therapeutics Ltd., a specialty life sciences company focused on developing innovative therapeutics for critical medical needs, has announced the closing of a second tranche of a private placement.
The private placement issued 4,352,381 units at a price of $0.021 per unit, bringing the total gross proceeds from the offering to $91,400. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one common share at an exercise price of $0.05 for a period of 36 months.
The private placement was announced on September 5, 2025, and all securities issued are subject to a hold period of four months and one day expiring on January 19, 2026. This means that the shares cannot be traded until the hold period expires.
The forward-looking information in this press release is based on reasonable assumptions made by Revive at the date of the information. However, the forward-looking information is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated. The risk factors are disclosed under the heading "Risk Factors" in the company's management's discussion and analysis for the three and nine months ended March 31, 2025.
Revive Therapeutics is not obligated to update or revise any forward-looking information, except as required by applicable securities laws. It is important to note that this press release contains forward-looking information regarding the company's cannabinoids, psychedelics, and infectious diseases programs.
For more information about Revive Therapeutics, please visit their website at www.revivethera.com. You can also contact them at Tel: 1 888 901 0036 or via email at [email protected].
It is worth noting that neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Revive Therapeutics is dedicated to developing innovative therapeutics for critical medical needs. The company's mission is to improve the quality of life for patients around the world.
In conclusion, Revive Therapeutics has successfully closed a second tranche of a private placement, raising $91,400 in gross proceeds. The funds will be used for working capital and payment of certain trade payables. As with any investment, it is important to consider the risks involved, and potential investors are encouraged to carefully review the company's risk factors.
Read also:
- Americans Lose Insurance Under New Tax Legislation, Affecting 10 Million Citizens
- Rising Number of Uninsured Individuals Could Put Strain on Local Healthcare Systems
- "Davina McCall frankly discusses her post-childbirth feelings toward returning to work"
- Older cancer patients face an elevated treatment challenge due to age-related health issues
